natgillin/translations-raw huggingface dataset:
Breast-feeding Talk to your doctor if you are breast-feeding or intending to breast-feed as breastfeeding should be discontinued if you take Thymanax.
Če jemljete zdravilo Thymanax, morate namreč prenehati z dojenjem.
Driving and using machines You might experience dizziness or sleepiness which could affect your ability to drive or operate machinery.
Vpliv na sposobnost upravljanja vozil in strojev Morda boste občutili vrtoglavico ali zaspanost, ki lahko vplivata na vašo sposobnost upravljanja vozil in strojev.
Important information about some of the ingredients of Thymanax
Pomembne informacije o nekaterih sestavinah zdravila Thymanax To zdravilo vsebuje laktozo.
If you have been told by your doctor that you have an intolerance to some sugars, talk to your doctor before taking Thymanax.
Če vam je zdravnik povedal, da imate intoleranco za nekatere sladkorje, se pred uporabo zdravila Thymanax posvetujte s svojim zdravnikom.
HOW TO TAKE THYMANAX
KAKO JEMATI ZDRAVILO THYMANAX
Always take Thymanax exactly as your doctor has told you.
Pri jemanju zdravila Thymanax natančno upoštevajte zdravnikova navodila.
In some cases, your doctor may prescribe a higher dose (50 mg), i. e. two tablets to be taken together at bedtime.
Nekaterim bolnikom lahko zdravnik predpiše večji odmerek (50 mg), to je dve tableti naenkrat pred spanjem.
Thymanax starts to act on symptoms of depression in most depressed people within two weeks of starting treatment.
20 Pri večini bolnikov zdravilo Thymanax začne zmanjševati simptome depresije v dveh tednih po začetku zdravljenja.
Your doctor will run laboratory tests to check that your liver is working properly at the initiation of treatment and then periodically during treatment, usually after 6 weeks, 12 weeks and 24 weeks.
Zdravnik bo opravil laboratorijske preiskave, da bi preveril, ali jetra delujejo pravilno, in sicer na začetku zdravljenja ter redno med njim, običajno po 6, 12 in 24 tednih.
If you take more Thymanax than you should If you have taken more Thymanax than you should, or if for example a child has taken medicine by accident, contact your doctor immediately.
Če ste vzeli večji odmerek zdravila Thymanax, kot bi smeli Če ste vzeli večji odmerek zdravila Thymanax, kot bi smeli, ali če je na primer zdravilo nehote vzel otrok, takoj obvestite svojega zdravnika.
The experience of overdoses with Thymanax is limited but reported symptoms include pain in the upper part of the stomach and drowsiness.
Izkušnje s prevelikim odmerjanjem zdravila Thymanax so omejene, poročali pa so o simptomih, kot so bolečine v zgornjem delu želodca in zaspanost.
If you forget to take Thymanax Do not take a double dose to make up for a forgotten dose.
Če ste pozabili vzeti zdravilo Thymanax Ne vzemite dvojnega odmerka, če ste pozabili vzeti prejšnji odmerek.
If you have any further questions on the use of this product, please ask your doctor or pharmacist.
Če imate dodatna vprašanja o uporabi zdravila, se posvetujte z zdravnikom ali s farmacevtom.
Like all medicines, Thymanax can cause side effects, although not everybody gets them.
Kot vsa zdravila ima lahko tudi zdravilo Thymanax neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
21 The frequency of possible side effects listed below is defined using the following system: • very common (affects more than 1 user in 10) • common (affects 1 to 10 users in 100) • uncommon (affects 1 to 10 users in 1,000) • rare (affects 1 to 10 users in 10,000) • very rare (affects less than 1 user in 10,000) • not known (frequency cannot be estimated from the available data)
Pogostnost morebitnih neželenih učinkov, ki so navedeni spodaj, je definirana na naslednji način: zelo pogosti (prizadenejo več kot 1 od 10 bolnikov)
These side effects include:
- pogosti (prizadenejo 1 do 10 od 100 bolnikov)
- Common side effects: dizziness, sleepiness (somnolence), difficulty in sleeping (insomnia),
- neznano (ni mogoče oceniti iz razpoložljivih podatkov)
migraine, headache, feeling sick (nausea), diarrhoea, constipation, upper abdominal pain, excessive sweating (hyperhidrosis), back pain, tiredness, anxiety, increased levels of liver enzymes in your blood.
Pogosti neželeni učinki: omotica, zaspanost, težave s spanjem (nespečnost), migrena, glavobol,
- Uncommon side effects: pins and needles in the fingers and toes (paraesthesia), blurred vision and
slabost, driska, zaprtje, bolečine v zgornjem delu trebuha, prekomerno znojenje, bolečine v hrbtu, utrujenost, anksioznost, zvečana vrednost jetrnih encimov v krvi.
- Rare side effects: serious skin eruption (erythematous rash), hepatitis.
Redki neželeni učinki: resni izpuščaji po koži (eritematozni izpuščaj), hepatitis.
- Other possible side effects: suicidal thoughts or behaviour (frequency not known).
- Drugi možni neželeni učinki: samomorilno obnašanje in razmišljanje o samomoru (pogostnost
If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
21 Če katerikoli neželeni učinek postane resen ali če opazite katerikoli neželeni učinek, ki ni omenjen v tem navodilu, obvestite svojega zdravnika ali farmacevta.
HOW TO STORE THYMANAX
SHRANJEVANJE ZDRAVILA THYMANAX
Do not use Thymanax after the expiry date which is stated on the carton and blister.
Zdravila Thymanax ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in pretisnem omotu.
What Thymanax contains
Kaj vsebuje zdravilo Thymanax
- The active substance is agomelatine.
- Zdravilna učinkovina je agomelatin.
• tablet core: lactose monohydrate, maize starch, povidone, sodium starch glycolate type A, stearic acid, magnesium stearate, colloidal anhydrous silica. • tablet film-coating: hypromellose, glycerol, macrogol, magnesium stearate, yellow iron oxide (E172) and titanium dioxide (E171). • printing ink: shellac, propylene glycol and indigotine (E132) aluminium lake
jedro tablete: laktoza monohidrat, koruzni škrob, povidon, natrijev karboksimetilškrob (vrsta A), stearinska kislina, magnezijev stearat, brezvoden koloidni silicijev dioksid;
What Thymanax looks like and contents of the pack Thymanax 25 mg film-coated tablets are oblong, orange-yellow with a blue imprint of ‘ company logo ’ on one side.
filmska obloga: hipromeloza, glicerol, makrogol, magnezijev stearat, rumeni železov oksid (E172), titanov dioksid (E171);
Thymanax 25 mg film-coated tablets are available in calendar blisters.
Izgled zdravila Thymanax in vsebina pakiranja Thymanax 25 mg filmsko obložene tablete so podolgovate, oranžnorumene z modrim odtisom (logotip podjetja) na eni strani.
Packs contain 7, 14, 28, 42, 56, 84 or 98 tablets.
Thymanax 25 mg filmsko obložene tablete so na voljo v koledarskih pretisnih omotih po 7, 14, 28, 42, 56, 84 ali 98 filmsko obloženih tablet.
Marketing Authorisation Holder Servier (Ireland) Industries Ltd Gorey road, Arklow, Co.
Imetnik dovoljenja za promet z zdravilom Servier (Ireland) Industries Ltd Gorey road, Arklow, Co.
Servier (Ireland) Industries Ltd Gorey road Arklow – Co.
Servier (Ireland) Industries Ltd Gorey road Arklow - Co.
Wicklow – Ireland
Wicklow Irska
Anpharm Przedsiebiorstwo Farmaceutyczne S. A.
22 Anpharm Przedsiebiorstwo Farmaceutyczne S. A. ul.
Annopol 6B Poland
Annopol 6B 03- 236 Warszawa Poljska
Latvija SIA Servier Latvia Tel: +371 67502039
Latvija SIA Servier Latva Tel: +371 7502039
This leaflet was last approved in {date}
Navodilo je bilo odobreno {MM/ LLLL}.
Detailed information on this medicine is available on the European Medicines Agency (EMEA) web site http: / /www. emea. europa. eu/
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila (EMEA) http: // www. emea. europa. eu /.
Thyrogen is a powder to be made up into a solution for injection.
Zdravilo Thyrogen je prašek, namenjen za pripravo raztopine za injiciranje.
Each vial contains 0.9 mg of the active substance thyrotropin alfa.
Vsaka viala vsebuje 0, 9 mg učinkovine tirotropin alfa.
Thyrogen is used in patients who have had an operation to remove their thyroid gland (thyroidectomy) because they had cancer.
Zdravilo Thyrogen se uporablja pri bolnikih, pri katerih je bila zaradi ugotovljenega raka izvedena operacijska odstranitev ščitnice (tiroidektomija).
Thyrogen is used with a ‘ thyroglobulin test’ and with or without a scan using radioactive iodine (131I) to detect any thyroid cells that might have been left over after surgery.
Zdravilo Thyrogen se uporablja v povezavi s tiroglobulinskim testom ter z ali brez slikanja z radioaktivnim jodom (131I) za odkrivanje celic ščitnice, ki so morda ostale po operaciji.
Thyrogen can also be used in combination with higher doses of radioactive iodine to ablate (kill) any remaining thyroid cells.
Zdravilo Thyrogen se lahko uporablja tudi v kombinaciji z večjimi odmerki radioaktivnega joda za odstranjevanje (uničevanje) preostalih celic ščitnice.
It is given as two 0.9-mg injections into the buttock muscle, 24 hours apart.
Zdravilo se daje v obliki dveh 0, 9 mg injekcij v mišico zadnjice v razmiku 24 ur.
When Thyrogen is used with a radioactive iodine scan, the iodine should be given 24 hours after the final Thyrogen injection, and the scan carried out 48 to 72 hours after this.
Ko se zdravilo Thyrogen uporablja v povezavi s slikanjem z radioaktivnim jodom, je treba jod aplicirati 24 ur po zadnji injekciji zdravila Thyrogen, slikanje pa se izvede 48 do 72 ur kasneje.
When Thyrogen is given with higher doses of radioactive iodine in ablation therapy, the iodine is also given 24 hours after the final Thyrogen injection, but the scan to see if all remaining cells have been ablated will need to be carried out after a longer delay (a few days).
Ko se zdravilo Thyrogen uporablja z večjimi odmerki radioaktivnega joda za odstranitev preostalih celic ščitnice, je treba jod aplicirati ravno tako 24 ur po zadnji injekciji zdravila Thyrogen, vendar pa se slikanje z namenom ugotavljanja, ali so bile vse preostale celice odstranjene, izvede z večjo zakasnitvijo (po nekaj dnevih).
The active substance in Thyrogen, thyrotropin alfa, is used to test thyroid function.
Zdravilna učinkovina v zdravilu Thyrogen, tirotropin alfa, se uporablja za testiranje delovanja ščitnice.
It is a copy of the natural hormone thyroid stimulating hormone (TSH).
Ta snov je kopija naravnega hormona ščitnico stimulirajoči hormon (TSH).
It has been produced by a method known as ‘ recombinant DNA technology’: the thyrotropin alfa is made by a cell that has received a gene (DNA), which makes it able to produce the hormone.
Proizvaja se po metodi, imenovani „ rekombinantna DNA tehnologija “: tirotropin alfa proizvaja celica, ki je prejela gen (DNA), ki ji omogoča tvorjenje hormona.
Patients whose thyroid has been removed receive replacement therapy with thyroxine (a hormone produced by the thyroid gland), which causes any thyroid cells remaining in their body to become inactive, and to stop producing TSH.
Bolniki, ki jim je bila ščitnica odstranjena, prejemajo nadomestno zdravljenje s tiroksinom (hormonom, ki ga proizvaja ščitnica), kar povzroči deaktiviranje morebitnih preostalih celic ščitnice v njihovem telesu, ki prenehajo proizvajati TSH.
However, TSH is needed when doctors are looking for leftover thyroid cells after surgery, as active cells are easier to detect.
Vendar pa je TSH potreben, ko zdravniki iščejo preostale celice ščitnice po operaciji, saj je aktivne celice lažje zaznati.
When Thyrogen is given, it acts like TSH and stimulates all leftover cells in the thyroid, including cancer cells.
Pri uporabi zdravila Thyrogen le- to deluje kot TSH in vzpodbuja delovanje vseh preostalih celic v ščitnici, vključno z rakavimi celicami.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Tedaj je njihovo aktivnost mogoče ugotoviti z merjenjem koncentracije beljakovine, imenovane tiroglobulin, ali z uporabo tehnike slikanja z radioaktivnim jodom, saj aktivne celice 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail@emea. europa. eu http: / /www. emea. europa. eu ©EMEA 2008 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged How has Thyrogen been studied?
(44- 20) 74 18 84 00 Fax (44- 20) 74 18 84 16 E- mail: mail@ emea. europa. eu http: // www. emea. europa. eu ©EMEA 2008 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged ščitnice privzamejo jod ter tako postanejo vidne na sliki.
Thyrogen has been studied in two studies involving a total of 406 patients who had had a thyroidectomy and needed a test to detect any remaining thyroid cells.
Zdravilo Thyrogen so preučevali v dveh glavnih študijah s skupno 406 bolniki, pri katerih je bila izvedena tiroidektomija in pri katerih je bilo potrebno izvesti test, da bi odkrili morebitne preostale celice ščitnice.
Each patient ’ s production of thyrogobulin and uptake of radioactive iodine were measured twice, once after treatment with Thyrogen and once when the patient was using thyroid hormone suppression therapy (THST).
Pri vsakem bolniku so dvakrat izmerili tvorbo tiroglobulina in privzem radioaktivnega joda, in sicer enkrat po zdravljenju z zdravilom Thyrogen in enkrat pri nadomestnem zdravljenju s ščitničnimi hormoni (THST - thyroid hormone suppression therapy).
THST is a way of restoring the natural body production of TSH by stopping replacement therapy with thyroxine for four to six weeks.
Prekinitev THST je način ponovne vzpostavitve naravne tvorbe TSH v telesu s prekinitvijo nadomestne terapije s tiroksinom za štiri do šest tednov.
The results of the two tests were compared to see if they were in agreement.
Dobljene rezultate obeh testov so primerjali, da bi ugotovili, ali se skladajo.
Thyrogen has also been studied in the ablation of thyroid tissue in one study involving 63 patients with thyroid cancer, who received 131I either after Thyrogen or after THST.
Zdravilo Thyrogen so preučevali tudi pri odstranjevanju ščitničnega tkiva v eni raziskavi s 63 bolniki z rakom ščitnice, ki so prejeli 131I bodisi po zdravilu Thyrogen bodisi po prekinitvi THST.
The main measure of effectiveness was based on a check eight months after treatment to see if the patient had any thyroid cells remaining.
Glavno merilo učinkovitosti je temeljilo na kontroli osem mesecev po zdravljenju, pri kateri so ugotavljali, ali ima bolnik še celice ščitnice.
What benefit has Thyrogen shown during the studies?
Kakšne koristi je zdravilo Thyrogen izkazalo med raziskavami?
In the detection of leftover thyroid cells, using Thyrogen to stimulate thyroglobulin production and uptake of radioactive iodine was comparable to using THST.
Pri zaznavanju preostalih celic ščitnice je bila uporaba zdravila Thyrogen za stimuliranje tvorbe tiroglobulina in privzema radioaktivnega joda primerljiva z uporabo THST.
Using Thyrogen allows patients to remain on their replacement therapy before the test is carried out, resulting in a better quality of life.
Uporaba zdravila Thyrogen bolnikom omogoča, da ostanejo pred izvedbo testa na nadomestnem zdravljenju, kar jim zagotavlja višjo kakovost življenja.
For the ablation of thyroid tissue, radioiodine imaging eight months after treatment showed that both treatments were 100% successful.
Pri odstranjevanju ščitničnega tkiva je slikanje z radioaktivnim jodom osem mesecev po zdravljenju pokazalo, da sta bila oba načina zdravljenja 100% uspešna.
The most common side effect with Thyrogen (seen in more than 1 patient in 10) is nausea (feeling sick).
Najpogostejši neželeni učinek zdravila Thyrogen (opažen pri več kot 1 izmed 10 bolnikov) je navzeja (slabost).
For the full list of all side effects reported with Thyrogen, see the Package Leaflet.
Za celoten seznam vseh neželenih učinkov, o katerih so poročali pri uporabi zdravila Thyrogen, glejte Navodilo za uporabo.
Thyrogen should not be used during pregnancy.
Zdravila Thyrogen se ne sme uporabljati med nosečnostjo.
The Committee for Medicinal products for Human Use (CHMP) decided that Thyrogen’ s benefits are greater than its risks for use in post-thyroidectomy patients maintained on hormone suppression therapy (THST) for the detection of thyroid remnants and well-differentiated thyroid cancer (with serum thyroglobulin testing with or without radioiodine imaging) and for the ablation of thyroid remnant tissue in combination with radioactive iodine (131I).
Odbor za zdravila za uporabo v humani medicini (CHMP) je odločil, da so koristi zdravila Thyrogen pri uporabi pri bolnikih, ki po tiroidektomiji prejemajo nadomestno zdravljenje s ščitničnimi hormoni (THST), za odkrivanje ostankov ščitnice in dobro diferenciranega raka ščitnice (s testiranjem tiroglobulina v serumu z ali brez slikanja z radioaktivnim jodom) ter za odstranjevanje ostankov ščitničnega tkiva v kombinaciji z radioaktivnim jodom (131I) večje od z njim povezanih tveganj.
The Committee recommended that Thyrogen be given marketing authorisation.
Odbor je zato priporočil, da se za zdravilo Thyrogen podeli dovoljenje za promet.
Other information about Thyrogen:
Druge informacije o zdravilu Thyrogen:
The European Commission granted a marketing authorisation valid throughout the European Union for Thyrogen to Genzyme Europe B. V. on 9 March 2000.
Evropska komisija je dovoljenje za promet z zdravilom Thyrogen, veljavno po vsej Evropski uniji, odobrila družbi Genzyme Europe B. V. dne 9. marca 2000.
The full EPAR for Thyrogen is available here.
Celotno Evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Thyrogen je na voljo tukaj.
Pharmaceutical form
Pot uporabe
Route of administration Packaging
Ovojnina
Package size
Viala, steklo
Powder for solution for injection Powder for solution for injection
Prašek za raztopino za injiciranje
Intramuscular use Vial, glass Intramuscular use Vial, glass
Viala, steklo
Thyrogen 0.9 mg powder for solution for injection
Thyrogen 0, 9 mg prašek za raztopino za injiciranje
Each vial of Thyrogen contains a nominal value of 0.9 mg thyrotropin alfa.
Ena viala zdravila Thyrogen vsebuje nominalno vrednost 0, 9 mg tirotropina alfa.
Following reconstitution, each vial of Thyrogen contains 0.9 mg of thyrotropin alfa in 1.0 ml.
Po rekonstituciji vsebuje ena viala zdravila Thyrogen 0, 9 mg tirotropina alfa v 1, 0 ml.
White to off-white lyophilised powder.
Beli do umazano beli lipofilni prašek.
Thyrogen (thyrotropin alfa) is indicated for use with serum thyroglobulin (Tg) testing with or without radioiodine imaging for the detection of thyroid remnants and well-differentiated thyroid cancer in post-thyroidectomy patients maintained on hormone suppression therapy (THST).
Thyrogen (tirotropin alfa) je indiciran za uporabo pri določanju koncentracije tiroglobulina (Tg) v serumu z ali brez scintigrafije z radioaktivnim jodom za odkrivanje tiroidnih ostankov in dobro diferenciranega raka ščitnice pri bolnikih, ki se po tiroidektomiji zdravijo s hormonsko supresivno terapijo (THST - ´thyroid hormone suppression treatment´).
Low risk patients with well-differentiated thyroid carcinoma who have undetectable serum Tg levels on THST and no rh TSH-stimulated increase of Tg levels may be followed-up by assaying rh TSH-stimulated Tg levels.
Pri nizko ogroženih bolnikih z dobro diferenciranim rakom ščitnice in neopaznimi vrednostmi Tg v serumu pri THST ter brez rh TSH- stimuliranega zvišanja koncentracije Tg lahko nadaljujemo z določanjem rh TSH- stimulirane koncentracije Tg.
Thyrogen (thyrotropin alfa) is indicated for pre-therapeutic stimulation in low risk (see section 5.1) post-thyroidectomy patients maintained on hormone suppression therapy (THST) for the ablation of thyroid remnant tissue (in combination) with 100 mCi (3.7 GBq) radioactive iodine (131I).
Thyrogen (tirotropin alfa) je indiciran za predterapevtsko stimulacijo pri nizko ogroženih bolnikih (glejte poglavje 5. 1), ki se po tiroidektomiji zdravijo s hormonsko supresivno terapijo (THST), za ablacijo ostankov tiroidnega tkiva (v kombinaciji) s 100 mCi (3. 7 GBq) radioaktivnega joda (131I).
The recommended dose regimen is two doses of 0.9 mg thyrotropin alfa administered at a 24-hour interval by intramuscular injection only.
Priporočena shema odmerjanja sta dva odmerka po 0, 9 mg tirotropina alfa v razmiku 24 ur, ki ju damo samo z intramuskularno injekcijo.
After reconstitution with water for injection, 1.0 ml solution (0.9 mg thyrotropin alfa) is administered by intramuscular injection to the buttock.
Po rekonstituciji z vodo za injekcije 1, 0 ml raztopine (0, 9 mg tirotropina alfa) injiciramo v zadnjico z intramuskularno injekcijo.
See section 6.6 for instructions for handling.
Glejte poglavje 6. 6 za navodila za ravnanje z zdravilom.
Diagnostic scintigraphy should be performed 48 to 72 hours following radioiodine administration, whereas post-ablation scintigraphy may be delayed additional days to allow background activity to decline.
Diagnostično scintigrafijo izvršimo 48 ali 72 ur po prejetju radioaktivnega joda, medtem ko lahko scintigrafijo po ablaciji odložimo za nekaj dni, da se zmanjša aktivnost v ozadju.
For diagnostic follow-up serum thyroglobulin (Tg) testing, the serum sample should be obtained 72 hours after the final injection of Thyrogen.
2 Za diagnostično določitev tiroglobulina v serumu (Tg) moramo vzorec seruma vzeti 72 ur po zadnjem injiciranju zdravila Thyrogen.
Due to a lack of data on the use of Thyrogen in children, Thyrogen should be given to children only in exceptional circumstances.
Zaradi pomanjkanja podatkov o uporabi zdravila Thyrogen pri otrocih lahko Thyrogen dajemo otrokom samo v izrednih okoliščinah.
Information from post marketing surveillance, as well as published information, suggests that elimination of Thyrogen is significantly slower in dialysis-dependent end stage renal disease (ESRD) patients, resulting in prolonged elevation of TSH levels for several days after treatment.
Informacije pridobljene po začetku trženja in objavljene informacije kažejo, da je izločanje zdravila Thyrogen pomembno upočasnjeno pri bolnikih s končno stopnjo ledvične bolezni (ESRD - "endstage renal disease"), ki so odvisni od dialize, kar povzroči podaljšan povečanje ravni TSH še nekaj dni po zdravljenju.
This may lead to increased risk of headache and nausea.
To lahko povzroči povečano tveganje glavobola in navzee.
There are no studies of alternative dose schedules of Thyrogen in patients with ESRD to guide dose reduction in this population.
Študij alternativnih režimov odmerjanja zdravila Thyrogen pri bolnikih z ESRD, ki bi vodili v zmanjšanje odmerka pri tej populaciji niso izvajali.
Use of Thyrogen with Tg testing in follow up of post-thyroidectomy well differentiated thyroid cancer patients should be in accordance with official guidelines.
Uporaba zdravila Thyrogen z določanjem Tg za spremljanje posttiroidektomijskih bolnikov z dobro diferenciranim rakom ščitnice mora biti v skladu z uradnimi smernicami.
· Hypersensitivity to bovine or human thyroid stimulating hormone or to any of the excipients.
· Preobčutljivost za ščitnico stimulirajoči hormon govejega ali človeškega izvora ali katerokoli
· Pregnancy.
· Nosečnost.
Thyrogen should not be administered intravenously.
Thyrogena ne smemo dajati intravensko.
When used as an alternative to thyroid hormone withdrawal, the combination of the whole body scintigraphy (WBS) and Tg testing after Thyrogen administration assures the highest sensitivity for detection of thyroid remnants or cancer.
Kadar uporabljamo kombinacijo scintigrafije celotnega telesa (Whole Body Scintigraphy, WBS) in določanja Tg kot alternativo odstranitvi tiroidnega hormona, le- ta zagotavlja po dajanju zdravila Thyrogen najvišjo stopnjo občutljivosti pri zaznavanju tiroidnih ostankov ali raka.
False negative results may occur with Thyrogen.
Z zdravilom Thyrogen lahko dobimo tudi napačne negativne rezultate.
If a high index of suspicion for metastatic disease persists, a confirmatory withdrawal WBS and Tg testing should be considered.
Če obstaja močan sum metastatske bolezni, razmislite o dodatnem potrdilnem določanju WBS in Tg.